The most compelling evidence is the interim results from the latest Randomised Controlled Trial in America.
The most compelling evidence is the interim results from the latest Randomised Controlled Trial in America. This double-blind trial took place across 5 facilities with 51 patients who’d all had a CAUTI diagnosed with antibiotics administered 30 days prior, with an initial bacterial load of >100,000 CFU in the urinary tract. 
Patients in the control group were fitted with a placebo device which mimicked the treatment device exactly in appearance and features. After 30 days all control patients’ CFU remained at the 100,000 CFU mark, 15/26 in the treatment group had 10,000 CFU, with 10 patients’ at 1,000 CFU. Only 1/26 in the treatment group developed a CAUTI needing systemic antibiotics, while 13/25 control patients required antibiotics. The comparison of 4% to 52% CAUTI rate is statistically significant, and shows great promise for the chronically catheterised with recurrent CAUTI